Posts

Relapsed or Refractory Metastatic Colorectal Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Relapsed or Refractory Metastatic Colorectal Cancer  Market Outlook Thelansis’s “Relapsed or Refractory Metastatic Colorectal Cancer   Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Metastatic Colorectal Cancer   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Relapsed or Refractory Metastatic Colorectal Cancer   Overview Colorectal cancer (CRC) is the 3rd commonest cause of cancer death. Approximately 25% of patients have metastatic disease at diagnosis, and about 50%-60% of patients diagnosed with CRC further progressed to develop metastatic disease. Visceral obesity has been reported to...
Post a Comment
Read more

Anti-Glomerular Basement Membrane (anti-GBM) Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Anti-Glomerular Basement Membrane (anti-GBM) Disease  Market Outlook Thelansis’s “Anti-Glomerular Basement Membrane (anti-GBM) Disease   Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Anti-Glomerular Basement Membrane (anti-GBM) Disease   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Anti-Glomerular Basement Membrane (anti-GBM) Disease   Overview Anti-Glomerular Basement Membrane (anti-GBM) Disease is a rare form of small vessel vasculitis that affects the kidney and lung capillary beds. It is an archetypic autoimmune disease caused by the development of directly pathogenic autoantibodies targeting a well-char...
Post a Comment
Read more

Recurrent Malignant Glioma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Recurrent Malignant Glioma  Market Outlook Thelansis’s “Recurrent Malignant Glioma   Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent Malignant Glioma   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Recurrent Malignant Glioma   Overview Malignant gliomas consist of glioblastomas, anaplastic oligodendrogliomas, anaplastic astrocytomas, and some less common tumors such as anaplastic ependymomas and anaplastic gangliogliomas. Malignant gliomas have high morbidity and mortality. With optimal treatment, the median survival for glioblastomas is only 12–15 months, and 2–5 years for anaplastic gliomas. Recent ...
Post a Comment
Read more

Liver Fibrosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Liver Fibrosis  Market Outlook Thelansis’s “Liver Fibrosis   Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Liver Fibrosis   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Liver Fibrosis   Overview Liver fibrosis is an ineffective wound-healing process of the liver in response to repeated and chronic injury from many etiologies, such as infectious diseases like viral hepatitis, metabolic derangements (non-alcoholic steatohepatitis), exposure to toxins (e.g., alcohol liver diseases), or autoimmune diseases (e.g., primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis). The morphology...
Post a Comment
Read more

Fuchs Endothelial Dystrophy (FED) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Fuchs Endothelial Dystrophy (FED)  Market Outlook Thelansis’s “Fuchs Endothelial Dystrophy (FED)   Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Fuchs Endothelial Dystrophy (FED)   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Fuchs Endothelial Dystrophy (FED)   Overview Fuchs endothelial dystrophy (FED) is a primary, progressive corneal endothelial disorder that causes corneal edema and vision loss. The first signs of FED usually appear between the fifth and seventh decades of life. They are characterized by progressive accumulation of focal excrescences, termed “guttae,” and thickening of Descemet’s membran...
Post a Comment
Read more

Relapsed / Refractory B-Acute Lymphocytic Leukemia (ALL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Relapsed / Refractory B-Acute Lymphocytic Leukemia (ALL)  Market Outlook Thelansis’s “Relapsed / Refractory B-Acute Lymphocytic Leukemia (ALL)   Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed / Refractory B-Acute Lymphocytic Leukemia (ALL)   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Relapsed / Refractory B-Acute Lymphocytic Leukemia (ALL)   Overview B-Cell Acute lymphoblastic leukemia (ALL) is a type of blood cancer in which many abnormal, immature lymphocytes known as blasts begin to multiply in the bone marrow. Lymphocytes are white blood cells that play a role in the immune response. B-ALL is c...
Post a Comment
Read more

B-Acute Lymphocytic Leukemia (ALL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

B-Acute Lymphocytic Leukemia (ALL)  Market Outlook Thelansis’s “B-Acute Lymphocytic Leukemia (ALL)   Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential B-Acute Lymphocytic Leukemia (ALL)   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). B-Acute Lymphocytic Leukemia (ALL)   Overview B-Cell Acute lymphoblastic leukemia (ALL) is a type of blood cancer in which many abnormal, immature lymphocytes known as blasts begin to multiply in the bone marrow. Lymphocytes are white blood cells that play a role in the immune response. B-ALL is characterized by the expression of various B–cell-specific antigens, which often include ...
Post a Comment
Read more